In this regard, Gandara and collaborators demonstrated that TMB testing in ctDNA, measured by hybrid capture-based NGS, correlates to the outcome of NSCLC patients treated with the anti-PD-L1 antibody atezolizumab, with high blood TMB (>16, 394 genes analyzed) being associated with better PFS [96]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.